ABCAM Plc Directorate Change (2480T)
October 11 2017 - 2:00AM
UK Regulatory
TIDMABC
RNS Number : 2480T
ABCAM Plc
11 October 2017
11 October 2017
ABCAM PLC
("Abcam" or "Company")
Directorate Change - Chairman
Cambridge UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools announces that its Chairman,
Murray Hennessy, has informed the Board that he has accepted a CEO
role and will therefore relinquish his Non-Executive Chairman
position and step down from the Board following the AGM in November
2017.
After three years as Chairman and six years on the Board, Murray
has decided to return to executive management in a company based in
the USA. Louise Patten, who is currently serving as Senior
Independent Director of Abcam, will take over as interim
Non-Executive Chairman at the conclusion of the AGM, once an
orderly handover is complete. A search for a permanent
Non-Executive Chairman will now commence. Mara Aspinall will be
appointed as the interim Senior Independent Director at the
conclusion of the AGM.
Murray Hennessy, Chairman, said:
"It has been a privilege to be Chairman at Abcam over the last
three years. I am proud of the achievements we have realised in
implementing the successful growth strategy we commissioned in 2013
which has ensured we remain the global leader in the sales of
research antibodies. I have complete confidence in the Board and
the executive team to sustain Abcam's long term growth. I am
leaving the company in a great position and I wish Alan and the
team the very best for the future."
Alan Hirzel, CEO, said:
"I would like to thank Murray for his support and advice since
my appointment as CEO over three years ago. I have been fortunate
to benefit from his experience and the passion he has demonstrated
for our business. His broad experience has helped us continue the
transformation of Abcam. We have a company that is stronger today
for Murray's contributions to the Board and I remain confident of
our outlook. I wish him every success in his new role. Louise has
previous experience as a FTSE Chairman, and I am looking forward to
working with her as interim Chairman."
##Ends##
For further information, please contact:
+ 44 (0) 1223
Abcam plc 696 000
Suzanne Smith, Company Secretary
Julia Wilson, Investor Relations
J.P.Morgan Cazenove - Nominated + 44 (0) 20 7742
Adviser & Corporate Broker 4000
James Mitford / Candelle Chong
FTI Consulting
Ben Atwell / Brett Pollard / +44 (0) 20 3727
Natalie Garland-Collins 1000
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's twelve locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
Forward looking statement
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADMMMGVGDGNZM
(END) Dow Jones Newswires
October 11, 2017 02:00 ET (06:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024